secwatch.observer — SEC 8-K summary
======================================

Issuer:     Upstream Bio, Inc. (UPB)
CIK:        0002022626
Form:       8-K
Filed at:   2025-03-12T23:59:59+00:00
Accession:  0000950170-25-037619
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Upstream Bio posts Q4 net loss $21.2M; CRSwNP Ph2 enrollment complete; cash through 2027
--------------------------------------------------------------------------------

- Net loss of $21.2M in Q4 2024 ($11.8M in Q4 2023); R&D expenses $21.8M vs $11.6M.
- Completed enrollment in Phase 2 CRSwNP trial of verekitug; top-line data expected H2 2025.
- Cash, equivalents and investments $470.5M as of Dec 31, 2024, funded by upsized IPO ($293M gross).
- Phase 2 severe asthma data expected H2 2026; first COPD patient dosing on track for H2 2025.
- Appointed Daniella Beckman to Board and Allison Ambrose as General Counsel in late 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2022626/000095017025037619/0000950170-25-037619-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2022626/000095017025037619/upb-20250312.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-037619

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer